Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 26, 2005. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the SmithKline Beecham Bonus Investment Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the share price of GBP13.73 per share, which was the price used for the re-investment of dividends paid on July 7, 2005.
Material Changes
The document reports an increase in the interest of specific individuals in Ordinary Shares. This change resulted from the re-investment of dividends rather than open market purchases or other material operational shifts. No comparative financial data or material changes to the company's financial position are detailed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It is strictly a regulatory disclosure of a specific transaction under Disclosure Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: July 26, 2005.
- Transaction Type: Increase in share interest via dividend re-investment.
- Share Price: GBP13.73 per share.
- Dividend Payment Date: July 7, 2005.
- Plan Involved: SmithKline Beecham Bonus Investment Plan.
- Participants: Mr. R Bondy and S M Bicknell (Company Secretary).